SLC22A5 and cancer: However, looking into our phenotypic data we can verify that CTD (SLC22A5), Parkinson ́s disease (LRPPRC), multiple sclerosis (IL4R), 3-MCCD (MCCC1), and different cancer types (FANCE, MAD1L1 and CD46) have been reported by the participants.